|
1
|
Hornebeck W, Emonard H, Monboisse JC and
Bellon G: Matrix-directed regulation of pericellular proteolysis
and tumor progression. Semin Cancer Biol. 12:231–241. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wilkins-Port CE, Higgins SP, Higgins CE,
Kobori-Hotchkiss I and Higgins PJ: Complex regulation of the
pericellular proteolytic microenvironment during tumor progression
and wound repair: functional interactions between the serine
rrotease and matrix metalloproteinase cascades. Biochem Res Int.
2012:4543682012.
|
|
3
|
Netzel-Arnett S, Hooper JD, Szabo R, et
al: Membrane anchored serine proteases: a rapidly expanding group
of cell surface proteolytic enzymes with potential roles in cancer.
Cancer Metastasis Rev. 22:237–258. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lu D, Yuan X, Zheng X and Sadler JE:
Bovine proenteropeptidase is activated by trypsin, and the
specificity of enteropeptidase depends on the heavy chain. J Biol
Chem. 272:31293–31300. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gladysheva IP, Wang D, McNamee RA, et al:
Corin overexpression improves cardiac function, heart failure, and
survival in mice with dilated cardiomyopathy. Hypertension.
61:327–332. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Folgueras AR, de Lara FM, Pendas AM, et
al: Membrane-bound serine protease matriptase-2 (Tmprss6) is an
essential regulator of iron homeostasis. Blood. 112:2539–2545.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guipponi M, Tan J, Cannon PZ, et al: Mice
deficient for the type II transmembrane serine protease,
TMPRSS1/hepsin, exhibit profound hearing loss. Am J Pathol.
171:608–616. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu Q: Type II transmembrane serine
proteases. Curr Top Dev Biol. 54:167–206. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Webb SL, Sanders AJ, Mason MD and Jiang
WG: Type II transmembrane serine protease (TTSP) deregulation in
cancer. Front Biosci. 16:539–552. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hashimoto T, Kato M, Shimomura T and
Kitamura N: TMPRSS13, a type II transmembrane serine protease, is
inhibited by hepatocyte growth factor activator inhibitor type 1
and activates pro-hepatocyte growth factor. FEBS J. 277:4888–4900.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu Q and Parry G: Hepsin and prostate
cancer. Front Biosci. 12:5052–5059. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen CH, Su KY, Tao MH, et al: Decreased
expressions of hepsin in human hepatocellular carcinomas. Liver
Int. 26:774–780. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Szabo R and Bugge TH: Type II
transmembrane serine proteases in development and disease. Int J
Biochem Cell Biol. 40:1297–1316. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kosa P, Szabo R, Molinolo AA and Bugge TH:
Suppression of Tumorigenicity-14, encoding matriptase, is a
critical suppressor of colitis and colitis-associated colon
carcinogenesis. Oncogene. 31:3679–3695. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lang JC and Schuller DE: Differential
expression of a novel serine protease homologue in squamous cell
carcinoma of the head and neck. Br J Cancer. 84:237–243. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Viloria CG, Peinado JR, Astudillo A, et
al: Human DESC1 serine protease confers tumorigenic properties to
MDCK cells and it is upregulated in tumours of different origin. Br
J Cancer. 97:201–209. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cal S, Quesada V, Garabaya C and
Lopez-Otin C: Polyserase-I, a human polyprotease with the ability
to generate independent serine protease domains from a single
translation product. Proc Natl Acad Sci USA. 100:9185–9190. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Okumura Y, Hayama M, Takahashi E, et al:
Serase-1B, a new splice variant of polyserase-1/TMPRSS9, activates
urokinase-type plasminogen activator and the proteolytic activation
is negatively regulated by glycosaminoglycans. Biochem J.
400:551–561. 2006. View Article : Google Scholar
|
|
19
|
Cantero D, Friess H, Deflorin J, et al:
Enhanced expression of urokinase plasminogen activator and its
receptor in pancreatic carcinoma. Br J Cancer. 75:388–395. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wallrapp C, Hahnel S, Muller-Pillasch F,
et al: A novel transmembrane serine protease (TMPRSS3)
overexpressed in pancreatic cancer. Cancer Res. 60:2602–2606.
2000.PubMed/NCBI
|
|
21
|
Uhland K, Siphos B, Arkona C, et al: Use
of IHC and newly designed matriptase inhibitors to elucidate the
role of matriptase in pancreatic ductal adenocarcinoma. Int J
Oncol. 35:347–357. 2009.PubMed/NCBI
|
|
22
|
Kilpatrick LM, Harris RL, Owen KA, et al:
Initiation of plasminogen activation on the surface of monocytes
expressing the type II transmembrane serine protease matriptase.
Blood. 108:2616–2623. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Min HJ, Lee Y, Zhao XF, et al: TMPRSS4
upregulates uPA gene expression through JNK signaling activation to
induce cancer cell invasion. Cell Signal. 26:398–408. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Deer EL, Gonzalez-Hernandez J, Coursen JD,
et al: Phenotype and genotype of pancreatic cancer cell lines.
Pancreas. 39:425–435. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vila MR, Lloreta J, Schussler MH, Berrozpe
G, Welt S and Real FX: New pancreas cancers cell lines that
represent distinct stages of ductal differentiation. Lab Invest.
72:395–404. 1995.PubMed/NCBI
|
|
26
|
Noel A, Gutierrez-Fernandez A, Sounni NE,
et al: New and paradoxical roles of matrix metalloproteinases in
the tumor microenvironment. Front Pharmacol. 3:1402012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ochi N, Tanasanvimon S, Matsuo Y, et al:
Protein kinase D1 promotes anchorage-independent growth, invasion,
and angiogenesis by human pancreatic cancer cells. J Cell Physiol.
226:1074–1081. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guo XZ, Xu JH, Liu MP, et al: KAI1
inhibits anchorage-dependent and -independent pancreatic cancer
cell growth. Oncol Rep. 14:59–63. 2005.PubMed/NCBI
|
|
29
|
Suzuki M, Kobayashi H, Kanayama N, et al:
Inhibition of tumor invasion by genomic down-regulation of
matriptase through suppression of activation of receptor-bound
pro-urokinase. J Biol Chem. 279:14899–14908. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu J, Ben QW, Yao WY, et al: BMP2 induces
PANC-1 cell invasion by MMP-2 overexpression through ROS and ERK.
Front Biosci. 17:2541–2549. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Touab M, Villena J, Barranco C, Arumi-Uria
M and Bassols A: Versican is differentially expressed in human
melanoma and may play a role in tumor development. Am J Pathol.
160:549–557. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Welman A, Sproul D, Mullen P, et al:
Diversity of matriptase expression level and function in breast
cancer. PLoS One. 7:e341822012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jung H, Lee KP, Park SJ, et al: TMPRSS4
promotes invasion, migration and metastasis of human tumor cells by
facilitating an epithelial-mesenchymal transition. Oncogene.
27:2635–2647. 2008. View Article : Google Scholar
|
